Is GMED a buy according to AI stock analysis?

GMED AI stock analysis does not classify Globus Medical as an automatic buy. The business quality and Q1 2026 execution look strong, but the stock trades below its 100-day and 200-day averages with Q2 results still unreported, so a buy decision depends on the August 6 print, valuation discipline, integration proof, and personal risk tolerance.

What is the GMED AI stock forecast?

The GMED AI stock forecast uses scenarios rather than a fixed target. Around the July 31 close of $78.79 and the 2026 non-GAAP EPS guidance midpoint near $4.75, the three-year framework points to a bearish area near $73, a base area near $108, and a bullish area near $147, depending on growth, margins, and exit multiples.

What technical levels matter for GMED?

The key GMED technical levels are support near $76 to $78 from the 20-day moving average and recent July day lows, resistance near $79.70 from the 50-day moving average, and the $83.64 to $83.94 zone from the 100-day and 200-day moving averages, with the $101.40 52-week high overhead.

Can AI predict GMED stock price?

No, AI cannot reliably predict stock prices. AI can organize Globus Medical filings, valuation math, technical levels, and risk scenarios, but future GMED returns still depend on procedure volume, product adoption, reimbursement, Nevro integration, the August 6 Q2 report, market multiples, and investor behavior.

How should I use this GMED AI trading strategy?

Use this GMED AI trading strategy as a checklist for scenarios, technical confirmation, risk controls, and monitoring data. It is not personalized advice, and any trade should be checked against live prices, position size, time horizon, and an invalidation plan.

What makes Globus Medical different from larger medtech peers?

Globus is more concentrated in musculoskeletal care, especially spine implants and enabling technologies, than diversified giants such as Medtronic or Johnson & Johnson. That focus can create faster organic growth when share gains work, but it also raises concentration and hospital capital-cycle risk.

What changed in this August 3, 2026 refresh?

The refresh re-fetched and cross-validated the quote, market cap, Q1 2026 results, TTM financials, balance sheet, valuation, analyst actions, and technical levels. Key updates include the $78.79 close, a $10.70 billion market cap, UBS initiating coverage with a Hold and $82 target, several July target cuts from Truist, RBC, Stifel, and Piper Sandler, higher short interest near 5.21% of shares, and Q2 2026 earnings scheduled for August 6.

Globus Medical, Inc. research snapshot

GMED AI Stock Analysis

GMED AI stock analysis as of the August 3, 2026 data cutoff reads Globus Medical, Inc. as a high-quality musculoskeletal technology company with a scaled spine franchise, enabling technologies such as the Excelsius ecosystem, and growth from organic share gains plus Nevro. The stock closed at $78.79 on July 31, 2026, with an implied market capitalization of about $10.70 billion, re-verified as $78.79 times 135.74 million shares outstanding, matching the StockAnalysis.com quote and statistics pages. Q1 2026 net sales were $759.9 million, up 27.0% as reported, with non-GAAP diluted EPS of $1.12, and the company reaffirmed 2026 revenue guidance of $3.18 to $3.22 billion while raising non-GAAP diluted EPS guidance to $4.70 to $4.80. TTM revenue is near $3.10 billion with TTM EPS near $4.29 and free cash flow near $610 million. Q2 2026 results are scheduled for August 6, 2026, after this cutoff, so they are not yet reflected here. The stock trades near 18.4x trailing earnings and 16.4x forward earnings with a net cash position near $683 million, but price sits below the 100-day and 200-day moving averages after the pullback from the $101.40 52-week high. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.

Current price

$78.79

Market cap

$10.70 billion

AI score

70 / 100

Rating

Quality medtech compounder at a fair multiple with earnings ahead

Trend status

Consolidation below the 100-day and 200-day averages

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: A-level information richness. Globus Medical has multi-year public filings including the Q1 2026 Form 10-Q filed on May 7, 2026, the Q1 2026 earnings release and call transcript, coverage from 15 analysts, and multiple third-party datasets. The August 3, 2026 refresh re-fetched and re-validated the key figures: the $78.79 close, $10.70 billion market cap, TTM financials, the March 31, 2026 balance sheet with $560.95 million cash, and the Q1 2026 results. These matched across StockAnalysis.com, SEC EDGAR XBRL, the Q1 2026 earnings release, and the Q1 2026 Form 10-Q.
bias Check: The main AI bias risk is extrapolating the strong Q1 2026 beat and the raised EPS guidance into a durable re-rating while under-weighting that Q2 2026 results are still unreported, that several analysts trimmed price targets in July 2026, that short interest rose to 7.07 million shares, and that price still sits below the 100-day and 200-day moving averages. The reverse check asks whether hospital capital budgets, reimbursement pressure, Nevro integration drag, and competitive launches can slow growth and compress the multiple.
ai Confidence: High for filings, market-cap math, TTM reported metrics, Q1 2026 results, and balance sheet figures that cross-validated across StockAnalysis.com, SEC EDGAR XBRL, the Q1 2026 earnings release, and the Q1 2026 Form 10-Q during the August 3, 2026 refresh. The StockAnalysis.com statistics page reports net cash of $683.35 million including long-term marketable securities, while the balance sheet page shows cash and short-term investments of $629.85 million and total debt of $115.22 million, so net cash is sensitive to which cash bucket is counted. Medium for forward valuation because Q2 results are pending and procedure mix, robot capital budgets, M&A synergy timing, and medtech multiples can shift quickly.
investment Certainty: Medium. Business quality and competitive position are clear, but the margin of safety depends on the August 6 Q2 print, hospital spending, and whether the stock can reclaim its longer-term moving averages.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Globus sells implants, enabling technologies, and related musculoskeletal tools that hospitals and surgeons use in spine, trauma, reconstructive, biomaterial, and neuromodulation procedures, with TTM revenue near $3.10 billion and a TTM gross margin near 68%.	High
Moat	The moat comes from surgeon familiarity, implant and robotics ecosystems, hospital contracting, scale after NuVasive, and proprietary enabling technology, not pure consumer brand pricing power.	Medium-high
Management	Keith Pfeil and Kyle Kline should be judged by the Q1 2026 record results, the raised 2026 EPS guidance, organic spine share gains, Excelsius adoption, Nevro integration returns, free cash flow conversion, and acquisition discipline.	Medium
Financial trend	TTM revenue rose to about $3.10 billion with TTM net income near $586.71 million and TTM EPS near $4.29. Q1 2026 net sales rose 27.0% to $759.9 million with non-GAAP diluted EPS of $1.12, and 2026 guidance calls for revenue of $3.18 to $3.22 billion and non-GAAP diluted EPS of $4.70 to $4.80.	High
Valuation	Using TTM EPS near $4.29, GMED traded near 18.4x earnings. Using the midpoint 2026 non-GAAP EPS guidance near $4.75, the stock was near 16.4x forward earnings with about a 5.7% free cash flow yield on TTM cash flow and a net cash position near $683 million.	Medium-high
Technical trend	Price closed at $78.79 on July 31, 2026, just above the 20-day moving average near $78.06 but below the 50-day near $79.72 and well below the 100-day near $83.64 and the 200-day near $83.94, with 14-day RSI near 49.8 and weak 14-day ADX near 13.8.	Medium
Risk level	Main risks are hospital capital budgets, pricing and reimbursement pressure, Nevro integration, competitive product launches, the unreported Q2 print, and multiple compression if growth slows or Q2 disappoints.	Medium-high
AI confidence	High for descriptive research and calculations that cross-validated across StockAnalysis.com, SEC EDGAR XBRL, the Q1 2026 earnings release, and the Q1 2026 Form 10-Q. Lower for exact price outcomes because Q2 results and medtech repricing around procedure data remain uncertain.	High data confidence
Investment certainty	Medium certainty. GMED looks like a high-quality scaled spine platform at a fair multiple, but a buy decision still depends on the Q2 print, price discipline, and integration proof.	Medium

GMED AI stock forecast

GMED AI Stock Forecast Scenarios

The GMED AI stock forecast uses scenario math around the July 31, 2026 close of $78.79 and the midpoint 2026 non-GAAP EPS guidance near $4.75. The three-year framework produced a bearish area near $73, a base area near $108, and a bullish area near $147 before capital-return effects, using EPS growth of 3%, 8%, and 12% and exit multiples of 14x, 18x, and 22x. These are scenarios, not price commitments.

Bullish case

$140 to $150

More likely if organic spine share gains continue, Excelsius and enabling technologies expand hospital accounts, Nevro integration improves, Q2 confirms the guidance path, and the market pays about 22x rising earnings.

Base case

$100 to $112

More likely if revenue grows near the high single digits, non-GAAP EPS compounds around high single digits, and investors value GMED near a mid-to-high-teens earnings multiple while integration stays orderly.

Bearish case

$68 to $78

More likely if hospital budgets slow robot and implant demand, pricing pressure rises, Q2 or Nevro integration disappoints, competitors take share, or investors compress the multiple toward the low teens.

GMED AI technical analysis

GMED AI Technical Analysis

GMED AI technical analysis is neutral to weak as of the August 3, 2026 data cutoff. The stock closed at $78.79 on July 31, 2026, just above the 20-day moving average near $78.06 but below the 50-day near $79.72 and below the 100-day near $83.64 and the 200-day near $83.94, with a neutral 14-day RSI near 49.8 and a weak 14-day ADX near 13.8. Q2 2026 earnings on August 6 are the next catalyst.

Level	Value	Why it matters
Current price	$78.79	StockAnalysis.com real-time quote at the July 31, 2026 close; market cap math uses 135.74 million shares outstanding.
Near support	$76 to $78	The 20-day moving average near $78.06 and recent July day lows around $77 form the first support zone under the July 31 close.
Near resistance	$79.70 to $83.60	The 50-day moving average near $79.72 is the first upside hurdle, with the 100-day near $83.64 above it.
50-day moving average	$79.72	Barchart and StockAnalysis.com both reported the 50-day moving average near $79.72, slightly above the recent spot price.
100-day moving average	$83.64	Barchart reported the 100-day moving average near $83.64, well above the July 31 close, so the medium-term trend still needs repair.
200-day moving average	$83.94	The longer-term average reference sat near $83.94, above the current price and the main trend barrier to reclaim.
Momentum	14-day RSI near 49.8, ADX near 13.8	Barchart showed a neutral RSI near 49.8 and a weak ADX near 13.8, indicating range behavior rather than a strong trend.
Volume	About 1.05 million shares on July 31 and about 1.6 million on the 20-day average	StockAnalysis.com and Barchart both showed average volume near 1.6 million shares, liquid enough to read breakout and breakdown moves.
Volatility	Elevated mid-cap medtech volatility	The 52-week range of $51.79 to $101.40 and 14-day historical volatility near 41.5% show large swing risk around growth, integration, and multiple changes.
Invalidation	Close below $76, then below $70	A decisive close below the $76 to $78 support would weaken the stabilization setup, and a move toward $70 or the $51.79 low would challenge the longer recovery thesis.

GMED AI trading strategy

GMED AI Trading Strategy Framework

The GMED AI trading strategy is a rules-based research framework for a scaled spine and enabling-technology compounder with Q2 results due August 6, 2026. It is not personal advice and should be paired with live quotes, filings, hospital capital indicators, and position sizing.

Trend-following setup

Watch for GMED to reclaim and hold the $79.70 to $83.60 resistance zone on improving volume, ideally with a constructive Q2 report on August 6, before treating the pullback as resolved.

A close back below $76 or a failed breakout after a hospital capital or guidance disappointment should invalidate the short-term setup.

Mean-reversion setup

If GMED dips into the $76 to $78 support without a new competitive, reimbursement, or integration problem, compare the reaction with the Q2 results and margin evidence before acting.

Do not average down without a defined loss limit because medtech stocks can reprice quickly when procedure growth or capital budgets disappoint.

Fundamental monitor

Track U.S. spine growth, international growth, base-business growth excluding Nevro, Enabling Technologies revenue, adjusted EBITDA margin, free cash flow, Excelsius placements, and Nevro integration milestones.

Reduce confidence if EPS growth depends mainly on one-time synergies, accounting adjustments, or multiple expansion rather than durable implant and enabling-technology demand.

Investment research summary

Four-master Research Compression

Business essence

Globus Medical converts surgeon preference, implant portfolios, and enabling technologies into recurring musculoskeletal procedure revenue across spine and adjacent orthopedic markets, with Q1 2026 net sales up 27.0%.

Moat

The moat is strongest where implant systems, robotics and navigation, training, and hospital relationships reinforce each other. It narrows if rivals match clinical outcomes at lower capital cost or better workflow.

Munger risk inversion

The thesis fails if organic growth fades after acquisition contribution rolls off, if hospitals delay robot and implant spend, if Nevro or prior deal integration destroys value, if Q2 disappoints, or if pricing pressure erodes margins.

Management

Keith Pfeil and Kyle Kline delivered record Q1 2026 results with 27% revenue growth and raised non-GAAP EPS guidance to $4.70 to $4.80, but future judgment depends on Nevro integration, synergy delivery, capital allocation, and free cash flow quality.

Industry trend

Spine and musculoskeletal care benefit from aging populations, procedural volume, and technology adoption, but the industry faces reimbursement pressure, hospital budget cycles, and intense device competition.

Valuation and margin of safety

At about 18.4x trailing earnings and 16.4x forward earnings with net cash near $683 million, GMED is priced fairly rather than cheap. Margin of safety depends on the Q2 print and continued high-single-digit growth, not on a distressed multiple.

Source-backed data

GMED Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
GMED price	$78.79 at the July 31, 2026 close	StockAnalysis.com real-time quote	August 3, 2026
Market capitalization	$10.70 billion, verified as $78.79 x 135.74 million shares	StockAnalysis.com quote and share statistics and financial_rigor.py	August 3, 2026
Shares outstanding	135.74 million	StockAnalysis.com statistics, matching the Q1 2026 Form 10-Q share counts	August 3, 2026
Q1 2026 net sales and EPS	$759.9 million net sales up 27.0%, GAAP diluted EPS $0.90 up 66.6%, non-GAAP diluted EPS $1.12 up 64.7%	Globus Medical Q1 2026 earnings release	May 7, 2026
Q1 2026 base business sales excluding Nevro	$677.2 million, up 13.2% as reported	Globus Medical Q1 2026 earnings release	May 7, 2026
Q1 2026 geographic and segment detail	U.S. net sales up 25.0%, international up 35.6% as reported; Musculoskeletal Solutions $732.98 million and Enabling Technologies $26.87 million	Globus Medical Q1 2026 earnings release	May 7, 2026
FY2026 company guidance	Revenue $3.18 to $3.22 billion reaffirmed and non-GAAP diluted EPS $4.70 to $4.80, raised from $4.40 to $4.50	Globus Medical Q1 2026 earnings release	May 7, 2026
FY2025 revenue and net income	FY2025 revenue $2.939 billion up 16.65%, net income $537.87 million, GAAP diluted EPS $3.92	StockAnalysis.com financials and FY2025 10-K	August 3, 2026
TTM financials	TTM revenue near $3.10 billion, net income near $586.71 million, EPS near $4.29, free cash flow near $610.32 million	StockAnalysis.com statistics and cash flow statement	August 3, 2026
Balance sheet as of March 31, 2026	Cash and cash equivalents $560.95 million, short-term marketable securities $68.90 million, long-term marketable securities $169.44 million, total cash and marketable securities $799.29 million, total debt $115.22 million	Globus Medical Q1 2026 Form 10-Q and SEC EDGAR XBRL	August 3, 2026
Net cash and enterprise value	Net cash near $683 million including long-term marketable securities per the statistics page, and enterprise value near $10.01 billion	StockAnalysis.com statistics	August 3, 2026
Valuation ratios	18.37x trailing PE, 16.40x forward PE, 17.52x price to free cash flow, 12.30x EV/EBITDA, 3.45x price to sales, about 5.7% FCF yield	StockAnalysis.com statistics	August 3, 2026
Analyst consensus	Buy with an average target of $103.92 across 15 analysts, low $82 and high $122, median $103	StockAnalysis.com forecast	August 3, 2026
Analyst rating mix, July 2026	7 Strong Buy, 3 Buy, 5 Hold, 0 Sell out of 15 analysts	StockAnalysis.com forecast recommendation trends	August 3, 2026
Recent analyst target updates	UBS initiated Hold at $82 on July 28, Truist lowered to $100 from $115 on July 16, RBC lowered to $115 from $120 on July 13, BMO initiated Buy at $94 on July 8, Stifel lowered to $80 from $95, Piper Sandler lowered to $100 from $115	StockAnalysis.com forecast and news feed	August 3, 2026
Short interest	7.07 million shares short, 5.21% of shares outstanding, 6.33% of float, 3.48 days to cover	StockAnalysis.com statistics short selling	August 3, 2026
Q2 2026 earnings date	Scheduled for after market close on August 6, 2026	Globus Medical press release on July 16, 2026	August 3, 2026
52-week range	$51.79 to $101.40	StockAnalysis.com quote snapshot	August 3, 2026
Technical snapshot	5-day SMA near $79.86, 20-day SMA near $78.06, 50-day SMA near $79.72, 100-day SMA near $83.64, 200-day SMA near $83.94, 14-day RSI near 49.8, 14-day ADX near 13.8, 14-day historical volatility near 41.5%	Barchart and StockAnalysis.com technical snapshots	August 3, 2026

Frequently Asked Questions

Read the MDT AI stock analysis View the SYK AI stock forecast Explore the ZBH AI technical analysis Compare AI stock picker ideas Build a rules-based trading strategy

This page is an informational research tool only and is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of August 3, 2026, and may be wrong if Globus Medical procedure volumes, hospital capital budgets, product adoption, the August 6 Q2 2026 report, Nevro or prior deal integration, competitive dynamics, reimbursement, or market multiples change.